Search

Crinetics Pharmaceuticals Inc

Suletud

SektorTervishoid

84.47 0.21

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

84.06

Max

84.37

Põhinäitajad

By Trading Economics

Sissetulek

7M

-121M

Müük

14M

25M

Aktsiakasum

-1.14

Kasumimarginaal

-481.149

Töötajad

594

EBITDA

-4.7M

-131M

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

+1.68% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

5. nov 2026

Turustatistika

By TradingEconomics

Turukapital

63M

8.9B

Eelmine avamishind

84.26

Eelmine sulgemishind

84.47

Uudiste sentiment

By Acuity

68%

32%

293 / 340 Pingereas Healthcare

Crinetics Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

11. aug 2026, 23:56 UTC

News

GrowGeneration reports second-quarter net sales of $43.2 million, a 5.5% increase. Shares are higher in after-market trading following the earnings announcement.

11. aug 2026, 23:56 UTC

News

Digital Realty Trust announced a quarterly dividend of $1.22 per share. Shares are trading higher in after-market hours following the announcement.

11. aug 2026, 23:56 UTC

News

UBS maintains Buy rating on Rapid7 and raises price target to $12. Shares are trading higher in after-market hours, reflecting positive investor sentiment.

11. aug 2026, 23:51 UTC

News

Codexis reported second-quarter revenues of $14.9 million, exceeding estimates. Shares are trading higher in after-market hours following the positive earnings report and guidance.

11. aug 2026, 23:51 UTC

News

Matthews International Corp names Michael J. Whitehead as CEO, succeeding Joseph C. Bartolacci. Shares are trading higher in after-market hours amid leadership transition optimism.

11. aug 2026, 23:46 UTC

News

Kilroy Realty Corp shares are higher in after-market trading following the departure of CFO Jeffrey Kuehling and the appointment of Eliott Trencher as interim CFO.

11. aug 2026, 23:46 UTC

News

Whirlpool Corp reported Q2 earnings that missed revenue and adjusted EPS expectations. Shares were roughly flat in after-market trading following the results.

11. aug 2026, 23:41 UTC

News

Clean Energy Fuels reported Q2 revenue of $106.4 million, exceeding expectations. The positive outlook for profitability growth boosted shares during after-market hours.

11. aug 2026, 23:41 UTC

News
Correlated Moves

BlackRock is joining Nvidia's $500 billion AI infrastructure initiative, though concerns about funding sustainability have contributed to lower after-market trading for the firm.

11. aug 2026, 23:41 UTC

News

Anterix shares fell in after-market trading despite a fiscal Q1 earnings beat, reporting net income of $240,000 and EPS of $0.01.

11. aug 2026, 23:41 UTC

News
Social Media

H&R Block reported fiscal 2026 revenue of $3.95 billion, exceeding expectations, and raised its dividend by 10%, contributing to a significant after-market increase.

11. aug 2026, 23:36 UTC

News

UBS upgraded Jabil Inc to Buy, maintaining a $430 price target. Shares are trading higher in after-market hours, supported by strong technical indicators.

11. aug 2026, 23:31 UTC

News

Ameresco Inc shares rose in after-market trading following strong Q2 earnings, reporting $515.5 million in revenue and raising full-year adjusted EPS guidance to $1.25.

11. aug 2026, 23:26 UTC

News
Social Media

Oracle Corp partners with Quantinuum to enhance cloud services with quantum computing. Shares are trading higher in after-market hours following the announcement.

11. aug 2026, 23:11 UTC

News
Social Media

General Motors shares declined in after-market hours following the announcement of a $4.5 billion Supplier Inventory Financing Program and plans to sell its battery joint venture stake.

11. aug 2026, 23:11 UTC

News
Social Media

Lumentum Holdings reported fiscal Q4 adjusted EPS of $3.23, exceeding estimates, and provided optimistic Q1 FY27 guidance, driving shares higher in after-market hours.

11. aug 2026, 23:06 UTC

News

Uber Technologies Inc. sold its entire stake in Serve Robotics, raising investor concerns about its delivery strategy. Shares traded lower during after-market hours.

11. aug 2026, 23:06 UTC

News

ATI Inc reported stronger second-quarter results, raising 2026 adjusted EBITDA guidance to $1.135 billion to $1.185 billion. Shares advanced in after-market hours.

11. aug 2026, 23:06 UTC

News

KKR & Co Inc has invested in Crowe Advisory LLC, enhancing service capabilities. Shares are trading higher in after-market hours following the announcement.

11. aug 2026, 23:06 UTC

News

SiTime Corp shares rose in after-market trading following a strong earnings report, highlighting 127% revenue growth and GAAP profitability.

11. aug 2026, 23:06 UTC

News

Blue Owl Capital prices $750 million in Senior Notes due 2036, aiming to repay borrowings. Shares are higher in after-market trading following the announcement.

11. aug 2026, 23:06 UTC

News

UBS initiated coverage on Century Aluminum Co with a Buy rating and a $60 price target, contributing to after-market gains.

11. aug 2026, 23:02 UTC

News

Agree Realty Corp declared a monthly cash dividend of $0.267, a 4.3% increase, contributing to a modest rise in shares during after-market hours.

11. aug 2026, 23:01 UTC

News

Siebert Financial Corp reports Q2 revenue of $31.2 million, up from $14.9 million last year. Shares are trading higher in after-market hours.

11. aug 2026, 23:01 UTC

News

Century Communities has acquired the Harbor Pointe community in Santa Ana. Shares are lower during after-market hours despite this expansion in Southern California.

11. aug 2026, 23:01 UTC

News

PagSeguro Digital shares rose in after-market hours following its Q2 earnings report, which showed a recurring net profit of 576 million reais, exceeding estimates.

11. aug 2026, 23:01 UTC

News
Event

Astronics Corporation reported second-quarter net income of $35.1 million and raised full-year revenue guidance, boosting shares higher in after-market trading.

11. aug 2026, 23:01 UTC

News

Arbor Realty Trust closed an $825 million collateralized loan obligation securitization, enhancing its balance sheet. Shares moved higher during after-market hours.

11. aug 2026, 23:01 UTC

News

Stereotaxis reported second-quarter revenue of $7.67 million, missing estimates and down from last year's $8.90 million. Shares traded roughly flat in after-market hours.

11. aug 2026, 23:01 UTC

News

Darling Ingredients announced a $150 million sale of production tax credits, boosting shares in after-market hours as investors react positively to the deal.

Võrdlus sarnastega

Hinnamuutus

Crinetics Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

1.68% tõus

12 kuu keskmine prognoos

Keskmine 85.56 USD  1.68%

Kõrge 95 USD

Madal 80 USD

Põhineb 14 Wall Streeti analüütiku instrumendi Crinetics Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

14 ratings

2

Osta

12

Hoia

0

Müü

Sentiment

By Acuity

293 / 340 Pingereas Tervishoid

Uudiste sentiment

Tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
help-icon Live chat